CLSA: US Proposed Restrictions on Outbound Biotech Investment Have Limited Impact; Gives Kelun-Biotech-B (06990.HK) "Outperform" Rating with Target Price of HK$626.4

Zhitong Finance APP has learned that CLSA issued a research report stating that it believes the proposed U.S. restrictions on outbound investment in biotechnology will have limited impact on Chinese biotech licensing transactions, and has given Kelun-Biotech-B (06990.HK) an "Outperform" rating with a target price of HK$626.4.